nofazinlimab + regorafenib

The **combination of nofazinlimab (formerly known as CS1003) and regorafenib** is an investigational cancer therapy combining a **humanized IgG4 monoclonal antibody targeting PD-1 (programmed cell death protein 1)** with **regorafenib**, a small molecule multi-kinase inhibitor. Nofazinlimab blocks the immune checkpoint PD-1 on T cells, enhancing the anti-tumor immune response, while regorafenib targets and inhibits multiple kinases involved in tumor angiogenesis, tumor growth, and the tumor microenvironment. This combination is being explored in clinical trials for the treatment of solid tumors, particularly in hepatocellular carcinoma and metastatic colorectal cancer, to potentially enhance anti-cancer efficacy through dual immunomodulation and anti-angiogenic effects[2][6][7].

Other names

CS1003 + regorafenibnofazinlimab + regorafenib